Funding Secured for Robotic Surgery Expansion
THINK Surgical, a California-based medical technology company, has finalized a debt facility agreement with Symbiotic Capital, securing up to $65 million in growth capital. The infusion is designated to support the commercial expansion of the company’s flagship robotic system and companion software designed for total knee arthroplasty (TKA) procedures.
According to terms disclosed by the company, the financing structure is staged to provide immediate liquidity and potential future capital based on operational performance. The agreement includes an initial disbursement of $25 million, with an additional $15 million contingent upon reaching specific milestones. The remaining $25 million is available as discretionary capital.
Technology and Market Positioning
The core of THINK Surgical’s portfolio is the TMINI handheld robotics system, which received US Food and Drug Administration (FDA) clearance in July 2024. The system operates in conjunction with the company’s TPLAN software, which utilizes pre-operative CT scans to generate 3D joint models. This allows surgeons to map implant alignment and select optimal components from various manufacturers before proceeding to the operating room.
A key aspect of THINK Surgical’s business model is its positioning as an open platform. The company reports that TMINI is currently compatible with approximately 70% of the total knee implant market. This strategy includes a limited distribution agreement signed with industry giant Zimmer Biomet in June 2024, which facilitates the integration of Zimmer Biomet technology into the TMINI platform.
Financial Outlook
Commenting on the capital raise, THINK Surgical CEO Stuart Simpson noted that the facility, alongside recent investments from existing stakeholders, is expected to provide the necessary runway to reach corporate profitability. Prior to this debt arrangement, the company had raised approximately $300 million through venture financing, private equity, and various equity offerings.
Context in the Orthopaedic Robotics Sector
The broader orthopaedic surgical robotics market remains a highly competitive space characterized by significant consolidation. Recent market data from GlobalData indicates that the sector is expanding at a compound annual growth rate (CAGR) of 5.6%, with an estimated valuation of $20.8 billion by 2035.
Current market dynamics show strong leadership from established players. As of 2025, GlobalData models suggest Stryker maintains a dominant position in the orthopaedic surgical robotics market with a 75.5% share, followed by Smith & Nephew at 10.4% and Zimmer Biomet at 9.5%. THINK Surgical continues to navigate this landscape by leveraging its open-platform compatibility to capture additional market share within the TKA segment.
